Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System

Farahidah Mohamed; May K Oo; Bappaditya Chatterjee; Batoul Alallam

doi:10.3389/fphar.2022.886981

Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System

Front Pharmacol. 2022 Jun 28:13:886981. doi: 10.3389/fphar.2022.886981. eCollection 2022.

Authors

Farahidah Mohamed¹, May K Oo¹, Bappaditya Chatterjee², Batoul Alallam³

Affiliations

¹ Pharmaceutical Technology Department, Kulliyyah of Pharmacy, International Islamic University Malaysia, Kuantan, Malaysia.
² Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies, Mumbai, India.
³ Cluster of Integrative Medicine, Advanced Medical and Dental Institute, University of Science Malaysia, Penang, Malaysia.

Abstract

Supramolecular mesoporous silica nanoparticles (MSNs) offer distinct properties as opposed to micron-sized silica particles in terms of their crystal structure, morphology-porosity, toxicity, biological effects, and others. MSN biocompatibility has touched the pharmaceutical realm to exploit its robust synthesis pathway for delivery of various therapeutic molecules including macromolecules and small-molecule drugs. This article provides a brief review of MSN history followed by special emphasis on the influencing factors affecting morphology-porosity characteristics. Its applications as the next-generation drug delivery system (NGDDS) particularly in a controlled release dosage form via an oral drug delivery system are also presented and shall be highlighted as oral delivery is the most convenient route of drug administration with the economical cost of development through to scale-up for clinical trials and market launch.

Keywords: insulin; mesoporous; nanoparticles; oral; pharmaceutical; silica.

Publication types

Review